Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia

Quizartinib is an FMS‐like tyrosine kinase 3 (FLT3) inhibitor that has shown robust clinical activity in patients with FLT3‐internal tandem duplication–mutated relapsed/refractory acute myeloid leukemia (AML). This analysis evaluated the population pharmacokinetics (PK) of quizartinib and its active...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Dongwoo, Ludwig, Elizabeth, Jaworowicz, David, Huang, Hannah, Fiedler‐Kelly, Jill, Cortes, Jorge, Ganguly, Siddhartha, Khaled, Samer, Krämer, Alwin, Levis, Mark, Martinelli, Giovanni, Perl, Alexander, Russell, Nigel, Abutarif, Malaz, Choi, Youngsook, Mendell, Jeanne, Yin, Ophelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689835/
https://www.ncbi.nlm.nih.gov/pubmed/32598495
http://dx.doi.org/10.1002/jcph.1680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689835/
https://www.ncbi.nlm.nih.gov/pubmed/32598495
http://dx.doi.org/10.1002/jcph.1680

Ejemplares similares